18 and older, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12Primary· Week 12
Number of participants who achieved ≥ 90% reduction in PASI compared to baseline.
Logistic regression analysis of PASI 90 response at Week 12
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, upper limbs, trunk, lower limbs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) t
Group
Value
95% CI
Secukinumab 300mg (2 x 150 mg)
366
Ustekinumab 2 x 45mg or 90mg
265
Participants With IGA Mod 2011 0 or 1 at Week 12Primary· Week 12
Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)
Group
Value
95% CI
Secukinumab 300mg (2 x 150 mg)
397
Ustekinumab 2 x 45mg or 90mg
306
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12Secondary· Week 12
Number of participants who achieved ≥ 75% reduction in PASI at Week 12 compared to baseline.
Group
Value
95% CI
Secukinumab 300mg (2 x 150 mg)
484
Ustekinumab 2 x 45mg or 90mg
409
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 4Secondary· Week 4
Number of participants who achieved ≥ 75% reduction in PASI at Week 4 compared to baseline.
Group
Value
95% CI
Secukinumab 300mg (2 x 150 mg)
221
Ustekinumab 2 x 45mg or 90mg
90
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 16Secondary· Week 16
Number of participants who achieved 100% reduction in PASI at Week 16 compared to baseline.
Group
Value
95% CI
Secukinumab 300mg (2 x 150 mg)
250
Ustekinumab 2 x 45mg or 90mg
147
Participants With IGA Mod 2011 0 or 1 at 16 WeeksSecondary· Week 16
Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)
Group
Value
95% CI
Secukinumab 300mg (2 x 150 mg)
432
Ustekinumab 2 x 45mg or 90mg
326
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 12Secondary· Week 12
Number of participants who achieved 100% reduction in PASI at Week 12 compared to baseline.
Group
Value
95% CI
Secukinumab 300mg (2 x 150 mg)
210
Ustekinumab 2 x 45mg or 90mg
111
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16Secondary· Week 16
Number of participants who achieved ≥ 75% reduction in PASI at Week 16 compared to baseline.
Group
Value
95% CI
Secukinumab 300mg (2 x 150 mg)
506
Ustekinumab 2 x 45mg or 90mg
441
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16Secondary· Week 16
Number of participants who achieved ≥ 90% reduction in PASI at Week 16 compared to baseline.
Group
Value
95% CI
Secukinumab 300mg (2 x 150 mg)
423
Ustekinumab 2 x 45mg or 90mg
299
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 52Secondary· Week 52
Number of participants who achieved ≥ 90% reduction in PASI at Week 52 compared to baseline.
Group
Value
95% CI
Secukinumab 300mg (2 x 150 mg)
402
Ustekinumab 2 x 45mg or 90mg
330
Adverse events — posted to ClinicalTrials.gov
Time frame: AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 52 months. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 52 weeks.
Reporting threshold: 2%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
· Phase 4
· not yet recruiting
NCT07477795 — Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
· Phase 2
· not yet recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
· Phase 4
· not yet recruiting
NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose
· recruiting
NCT06751238 — Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in
· Phase 1
· recruiting
Other recruiting trials for Plaque Psoriasis
Currently open trials in the same condition.
NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor
· Phase 3
· recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
· Phase 3
· recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit
· Phase 3
· recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
· NA
· recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
· Phase 3
· recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary
· Phase 3
· not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
· Phase 4
· not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
· not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
· not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+
· Phase 1, PHASE2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 9 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02826603.